Alfredo Addeo, Department of Oncology at the University Hospital of Geneva, shared on X:
“Hot off the press Editorial in JAMA.
With FLAURA2, MARIPOSA and now compelling data in EGFR/TP53 co-mutated disease, treatment intensification is increasingly becoming the standard. Key question remains: who can safely be spared intensification?
Our take: TP53 is clinically relevant, but its absence alone is not enough to justify de-escalation. Prospective de-escalation strategies are now needed. Great collaboration with Maxime Borgeaud and Shun Lu.”
Title: Is There Still Room for Monotherapy in EGFR-Mutated Non – Small Cell Lung Cancer?
Authors: Maxime Borgeaud, Shun Lu, Alfredo Addeo.
Read the full article.
To which Devika Das, Division Director of Hematology/Oncology at UMMC Cancer Center and Research Institute, added:
“I start out with a recommendation for intensification with all new patients and really need a strong contraindication to offer mono therapy alone in 2026. ( does happen) FLAURA 2 is my go to but MARIPOSA data is quite compelling as well. Most patients have 1 or the other risk factors in our population!”
You might be interested in:
